Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Prasugrel is emerging as the preferred antiplatelet drug for ACS patients after PCI. The SWITCH-SWEDEHEART trial found that making prasugrel the default choice reduced major bleeding compared to ticagrelor, without increasing ischemic events. A separate meta-analysis of 15 trials also ranked prasugrel first for the best balance of efficacy and safety among P2Y12 inhibitors.
Two new studies are adding momentum to the case for prasugrel as the first-line antiplatelet agent for acute coronary syndrome (ACS) patients undergoing PCI. The SWITCH-SWEDEHEART trial — presented at ESC Congress 2026 and published in the New England Journal of Medicine — took a novel approach by randomizing entire Swedish healthcare regions to either a prasugrel-first or ticagrelor-first prescribing policy, then tracking outcomes in over 17,000 patients. The result: fewer major bleeding events with prasugrel, and no uptick in ischemic complications.
Separately, a meta-analysis of 15 randomized trials published in JAMA Cardiology reinforced the same message — prasugrel outperformed both ticagrelor and clopidogrel on the efficacy-safety balance, with lower rates of MACE, MI, and stent thrombosis, and no excess bleeding risk.
By the Numbers
Why it matters: These findings give clinicians stronger evidence to favor prasugrel over ticagrelor in post-PCI ACS care — particularly given prasugrel's generic availability in Europe and its dose-adjustment flexibility for older or lower-weight patients. Experts note that antiplatelet de-escalation strategies remain the next frontier.
